NTRA — Natera, Inc. stock price, charts and financials

QT66Natera, Inc.

Natera, Inc. (NASDAQ: NTRA) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
366.31
+20.97+6.07%
NTRAQT66Natera, Inc.·NASDAQ
366.31+6.07%
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E-EPS (ttm)-1.36Insider Own3.55%Shs Outstand143.22MPerf Week12.32%
Market Cap52.46BForward P/E-EPS next Y-0.13Insider Trans-10.19%Shs Float136.92MPerf Month17.52%
Enterprise Value51.59BPEG-EPS next Q-0.22Inst Own-Short Float4.03%Perf Quarter61.77%
Income-193.00MP/S19.37EPS this Y0.92%Inst Trans-Short Ratio3.94Perf Half Y85.20%
Sales2.71BP/B28.81EPS next Y90.04%ROA-7.24%Short Interest5.51MPerf YTD59.90%
Book/sh12.72P/C48.04EPS next 5Y-ROE-11.73%52W High366.71 -0.11%Perf Year109.31%
Cash/sh7.62P/FCF-EPS past 3/5Y-ROIC-10.02%52W Low157.43 132.68%Perf 3Y571.27%
Dividend Est.-EV/EBITDA-Sales past 3/5Y41.15% 42.61%Gross Margin65.30%Volatility3.93% 3.39%Perf 5Y205.11%
Dividend TTM-EV/Sales19.05EPS Y/Y TTM11.11%Oper. Margin-10.70%ATR (14)12.12Perf 10Y3333.08%
Dividend Ex-Date-Quick Ratio2.85Sales Y/Y TTM59.58%Profit Margin-7.11%RSI (14)73.29Recom2.11
Dividend Gr. 3/5Y-Current Ratio3.00EPS Q/Q36.49%SMA209.97%Beta1.52Target Price335.07
Payout0.00%Debt/Eq0.12Sales Q/Q37.66%SMA5021.08%Rel Volume1.41Prev Close345.34
Employees6,138LT Debt/Eq0.07EarningsNov 05SMA20052.62%Avg Volume1.40MPrice366.31
IPO DateJul 01, 2015Option/ShortYes / YesEPS/Sales Surpr.4.85% 13.84%Net Debt/EBITDA4.76Volume1,965,687Change6.07%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-09-26ReiteratedUBSBuy$260$435
Sep-08-26InitiatedRothschild & Co RedburnBuy$385
Aug-12-26ReiteratedGuggenheimBuy$290$360
Aug-12-26ReiteratedStephens & Co.Overweight$54$350
Aug-10-26ReiteratedMorgan StanleyOverweight$310$355
Aug-07-26ReiteratedRobert W. Baird$379$348
Aug-07-26ReiteratedCanaccord GenuityBuy$330$375
Aug-07-26ReiteratedLeerink PartnersOutperform$280$330
Aug-07-26ReiteratedBarclaysOverweight$260$340
Aug-07-26ReiteratedRBC CapitalOutperform$275$350
Latest News· Times ET
Sep-14-26
Sep-11-26
Sep-10-26
Sep-08-26
Sep-04-26
Sep-02-26
Sep-01-26
Aug-31-26
Aug-29-26
Aug-28-26
Aug-27-26
Aug-26-26
Company

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2,7082,3061,697
Cost of Goods Sold Incl. D&A940811674
Gross Profit1,7671,4951,023
Selling, General and Administrative Excl. Other1,2551,177841
Research and Development787624404
Other Operating Expense1640
Operating Income-291-310-222
Interest Expense10411
Unusual Expense
Non-Operating Income (Expense)474643
Net Income Before Taxes-252-268-190
Income Taxes-61-601
Consolidated Net Income-193-208-190
Net Income From Continuing Operations-193-208-190
Net Income-193-208-190
EPS (Recurring)-1.36-1.52-1.53
EPS (Basic, Before Extraordinaries)-1.36-1.52-1.53
EPS (Diluted)-1.36-1.52-1.53
EBITDA-178-221-148
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio
Price To Sales Ratio19.3413.6111.66
Gross Margin65.2564.8360.28
Operating Margin-10.75-13.44-13.08
Net Margin-7.13-9.02-11.20
Shares Outstanding143137125
Market Capitalization52,38231,38519,788
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$401.21$325.60$249.98$174.37$98.76 Close Price0.00M14.41M28.83M43.24M57.66MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Rabinowitz MatthewEXECUTIVE CHAIRMANSep 15 '26Sale347.2952,00018,059,2920Sep 16
Rabinowitz MatthewEXECUTIVE CHAIRMANSep 14 '26Sale334.7650,00016,737,9762,175,394Sep 16
Rabinowitz MatthewEXECUTIVE CHAIRMANSep 11 '26Sale327.9750,00016,398,2672,225,394Sep 11
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSep 02 '26Sale326.8915,1604,955,713110,859Sep 03
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSSep 01 '26Sale320.733,000962,194126,019Sep 03
Chapman Steven LeonardCEO AND PRESIDENTSep 01 '26Sale320.991,698545,04198,199Sep 03
Fesko JohnPRESIDENT, CHIEF BUS. OFFICERAug 10 '26Sale321.536,5172,095,411197,257Aug 28
Sheena Jonathandirector, other: CO-FOUNDERAug 10 '26Sale325.326,0001,951,942230,464Aug 14
Sheena Jonathandirector, other: CO-FOUNDERAug 07 '26Sale315.669,1502,888,326236,464Aug 07
Rabinowitz MatthewEXECUTIVE CHAIRMANAug 07 '26Sale320.902,000641,8002,000Aug 07
Brophy Michael BurkesCHIEF FINANCIAL OFFICERAug 04 '26Sale274.22478131,07751,637Aug 05
Brophy Michael BurkesCHIEF FINANCIAL OFFICERAug 03 '26Sale267.9931784,95352,115Aug 05
Chapman Steven LeonardCEO AND PRESIDENTAug 03 '26Sale266.393,076819,43299,897Aug 05
Fesko JohnPRESIDENT, CHIEF BUS. OFFICERAug 03 '26Sale267.9929579,057183,774Aug 05
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICSAug 03 '26Sale265.583,410905,628129,019Aug 05
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.